Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 6/20 | 0.58 |
| ▸ | GSK3B | P49841 | 10/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5457579 | 0.83 | MAPK14 (0.61) | MAPK14GSK3BADORA2AADORA2BADORA1 | |
| SCHEMBL5449758 | 0.80 | MAPK14 (0.57) | MAPK14GSK3B | |
| SCHEMBL5459543 | 0.78 | MAPK14 (0.54) | MAPK14GSK3B | |
| SCHEMBL5452937 | 0.77 | MAPK14 (0.52) | MAPK14GSK3B | |
| SCHEMBL5461798 | 0.76 | MAPK14 (0.53) | MAPK14GSK3B | |
| SCHEMBL5875540 | 0.75 | MAPK14 (0.60) | MAPK14GSK3BADORA2AADORA2BADORA1 | |
| SCHEMBL5457469 | 0.74 | MAPK14 (1.00) | MAPK14GSK3BADORA2AADORA2BADORA1 | |
| SCHEMBL5463256 | 0.71 | MAPK14 (0.60) | MAPK14ADORA2AADORA2BADORA1 | |
| SCHEMBL5460102 | 0.70 | MAPK14 (0.58) | MAPK14 | |
| SCHEMBL5208663 | 0.69 | L3MBTL1 (0.43) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1377573-B1 | PYRAZOLOPYRIDINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2005-07-27 | — | — | EP | claimed |
| US-20070287721-A1 | Pyrazolopyridinyl pyridine | BOYD F LESLIE | 2007-12-13 | — | — | US | disclosed |
| US-20070287721-A1 | Pyrazolopyridinyl pyridine | BOYD F LESLIE | 2007-12-13 | — | — | US | disclosed |
| US-20070287721-A1 | Pyrazolopyridinyl pyridine | BOYD F LESLIE | 2007-12-13 | — | — | US | disclosed |
| US-7163940-B2 | Pyrazolopyridinyl pyrimidine therapeutic compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2007-01-16 | — | — | US | disclosed |
| US-7163940-B2 | Pyrazolopyridinyl pyrimidine therapeutic compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2007-01-16 | — | — | US | disclosed |
| EP-1377573-B1 | PYRAZOLOPYRIDINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2005-07-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287721-A1 | Pyrazolopyridinyl pyridine | CYP3A5, CYP2C19, CYP3A4 | MAPK14 2533/4885GSK3B 2943/4885ADORA2A 1286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.